



LAT1 & LAT2 in laryngeal cancer




Correlation between MIB-1 labeling index
and LAT1 staining index Breast Cancer

MIB-1


LAT1





Expression of LAT1 in renal carcinoma




LAT1/4F2hc high expression group exhibits poor prognosis in renal cancer







LAT1 and 4F2hc in T24 human bladder carcinoma cells




LAT1-mediated Leu transport in T24 cells



System L inhibitor



The effect of BCH on T24 cell growth



The effect of BCH on tumor growth

T24 cell tumor in nude mice

4 days after inoculation



Start vehicle injection



Start BCH injection

34 days after inoculation




Vehicle for 30 days





BCH for 30 days



BCH 258 mM 0.1 ml i.t. twice a day

The effect of BCH (i.t.) on T24 cell subcutaneous tumor






Survival of S-180 ascites tumor mice treated with antisense oligo DNA against LAT1



Substrate binding site of LAT1




Kinetic parameters

Compounds	LAT1		LAT2	
	K _i (μM)	K _m (μM)	K _i (μM)	K _m (μM)
Leucine	114	80.3	480	304
BCH	132		315	
melphalan	205		—	
T3	1.68		—	
T4	115		—	
KYT0193	0.12		0.28	
KYT0206	0.30		—	
KYT0213	1.57		0.56	

The effects on T24 cell growth


in vitro







Survival of S180 ascites tumor mice

by KYT0193


in vivo










Expression of LAT1 and 4F2hc in HEp-2 and T24 cells



Immunodetection of LAT1 and 4F2hc by Western blots




化学物質の構造式




Inhibition of cell growth by the inhibition of LAT1

A



BCH


B



KYT-0193


Inhibition of cell growth by cisplatin treatment

A



HEp-2 cells


B



T24 cells


Scatter plot analysis of the gene expression profiles

A



HEp-2 cells

B



HEp-2 cells

Summary of gene expression profiles in BCH- and cisplatin-treatments of HEp-2 cells

	BCH specific	Cisplatin specific	Common to BCH and cisplatin
Number of genes increased >2-fold	27	356	28
Number of genes decreased >2-fold	43	382	13



BCHとKYT0193で共通に変動する遺伝子に基づいた転写領域解析によるLAT1抑制の細胞内機序の探索



T24細胞 $20 \times 10^4 / 90 \text{ mm plate}$ 播種

対数増殖期開始時にBCH (20 mM)、KYT0193 (100 μM)投与
3時間、12時間後の遺伝子発現プロファイリングを行う。

CodeLink (Human Whole Genome) アマシャム

両化合物において共通に2倍以上の変化を示した遺伝子群を対象
とし、それらの遺伝子のcis elementを比較。





転写領域解析

K mean クラスター後、クラスターごとに解析した。

各遺伝子の転写開始点上流1000塩基と下流100塩基を解析の対象とした。

解析にはTOUCAN ver.2.2.0 (Stein Aerts and Peter Van Loo, Univ. of Leuven, Belgium)


TOUCANでの解析

1、各クラスター遺伝子群に優位に存在する予想転写因子結合サイトの検出

2、各クラスター遺伝子群に優位に存在する予想転写因子モジュール(複合体)の検出


TOUCANでの解析

1、各クラスター遺伝子群に優位に存在する予想転写因子結合サイトの検出



TOUCANでの解析

2、各クラスター遺伝子群に優位に存在する予想転写因子モジュール(複合体)の検出



トキシコロジーとトランスポーター

生体必須物質トランスポーターを標的とする毒性(薬効)の発現

薬物・外来性異物トランスポーターを介する毒性物質
(薬物)の細胞内侵入による毒性の発現
Transporter-mediated Toxicity